Sanofi Welcomes Australian Federal Government Medical Research and Clinical Trial Investment

Sydney, Australia – 19 May 2017 - Sanofi today welcomed the Australian Federal Government’s announcement to boost investment in medical research and clinical trials. 

Sanofi Australia and New Zealand Country Chair, Karen Hood, said that the funding demonstrated an important commitment not just to the nation’s health but to Australia’s position as a leading clinical trial destination. 
“While Australia has traditionally been an attractive destination for clinical trials international competition can be fierce with some countries now actively vying for more space,” she said. 
“By 2020, Sanofi alone expects its global R&D investment to top almost AU$9 billion each year. When you combine that with investment across the industry it’s plain to see the opportunity associated with attracting global biomedical research and clinical trials to our shores. 
“Today’s announcement, as part of the Federal Budget commitment of AU$1.4 billion over five years from the Medical Research Future Fund, will provide further confidence to the healthcare industry.” 
Karen noted that attracting ongoing research and clinical trial investment into Australia was a strong growth opportunity for the country. 
“Industry investment can deliver benefits to research institutions including universities and hospitals as well as the broader economy. Importantly, it also opens the door for potentially life changing, new innovations to reach Australian patients earlier – an opportunity we should all welcome.”

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile 2/2 economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.


Rebekah Miles

Rebekah Miles     

 0402 397 498